Enalaprilat: Difference between revisions
(Text replacement - "*Hyperkalemia" to "*Hyperkalemia") |
(Text replacement - "*CHF" to "*CHF") |
||
| Line 10: | Line 10: | ||
**CrCl <30 | **CrCl <30 | ||
**Severe volume or salt depletion, recent HD, or concomitant diuretic use | **Severe volume or salt depletion, recent HD, or concomitant diuretic use | ||
**CHF | **[[CHF]] | ||
==Pediatric Dosing== | ==Pediatric Dosing== | ||
''Safety/efficacy not established'' | ''Safety/efficacy not established'' | ||
Revision as of 17:34, 24 September 2016
Administration
- Type: ACE inhibitor
- Dosage Forms:
- Routes of Administration: IV
- Common Trade Names: Vasotec
Adult Dosing
- 1.25-5mg IV q6h
- 0.625mg IV initially, with repeated dose of 0.625mg if inadequate response for the following patients:
- CrCl <30
- Severe volume or salt depletion, recent HD, or concomitant diuretic use
- CHF
Pediatric Dosing
Safety/efficacy not established
Special Populations
- Pregnancy Rating: C
- Lactation risk: Infant risk minimal
Hepatic Dosing
- Adult:
- Pediatric:
Contraindications
- Allergy to class/drug
- Angioedema history (ACEi-induced, hereditary, or idiopathic)
Adverse Reactions
Serious
- Myocardial infarction
- Liver failure
- Angioedema
Common
- Hyperkalemia
- Nausea
- Headache
Pharmacology
- Half-life: ~11h
- Metabolism:
- Excretion: Renal. Dialyzable
Mechanism of Action
- Inhibits angiotensin converting enzyme, blocking conversion of angiotensin I to angiotensin II.